Overview
Chagas disease (American trypanosomiasis) is a vector-borne parasitic infection caused by Trypanosoma cruzi, transmitted primarily by blood-sucking insects of subfamily Triatominae. An estimated 6–7 million people are infected worldwide, with 75 million at risk. It is the leading cause of infectious cardiac disease in Latin America, kills more people annually in the Americas than any other parasitic disease including malaria, and remains one of the world's most consequential neglected tropical diseases.
The classic transmission picture, trypanosome to bug to human, is a teaching simplification. A wide range of mammal species can serve as reservoir hosts for T. cruzi, and the parasite cycles across sylvatic, peridomestic, and domestic environments through animals, insects, and people that move across those boundaries. Who is infecting whom? Who is the vector? In a transmission system this entangled, those are not simple questions. Untangling Chagas ecology is less like drawing a lifecycle than mapping a constellation: every mammal host, triatomine species, habitat edge, and human settlement adds another possible route. In practical terms, the system behaves less like a chain than an NP-hard graph. Kinetoplastid parasites have had hundreds of millions of years of evolutionary iteration; T. cruzi is not impressed by our grant funding.
The parasite did not begin in the house, but the house became part of its ecology. Human settlement, domestic animals, synanthropic mammals, and disturbed habitat edges create durable bridges between sylvatic and peridomestic transmission. In that sense, T. cruzi did not leave the jungle so much as acquire another room.
Global Burden (2025)
- 6–7 million infected worldwide
- 75 million at risk
- ~12,000 deaths per year
- Endemic in 21 Latin American countries
- Increasingly detected in USA, Europe, Japan
Pathogen
- Kingdom: Protozoa
- Phylum: Euglenozoa
- Class: Kinetoplastea
- Species: Trypanosoma cruzi
- 7 discrete typing units (DTU TcI–TcVI + Tcbat)
- Diploid; ~110 Mb genome
Primary Vectors
- Triatoma infestans (Southern Cone)
- Rhodnius prolixus (N. South America, C. America)
- Triatoma dimidiata (Central America, Mexico)
- Panstrongylus megistus (Brazil)
- >140 Triatominae species; ~30 epidemiologically relevant
Why "Neglected"
- Only two drugs; both ~60 years old
- Decades of silent cardiac damage before symptoms
- Disproportionately affects rural poor
- Chronic phase: no approved treatment outside children
- Massive underfunding relative to disease burden
Silent Epidemic: Up to 70% of chronically infected individuals are in the asymptomatic indeterminate phase and unaware of infection. When cardiac manifestations appear, arrhythmia, heart failure, sudden death, the damage is largely irreversible. Early diagnosis and treatment, especially during acute or congenital infection, provides the clearest path to parasitological cure.
Taxonomy and Classification
Trypanosoma cruzi was first described by the Brazilian physician Carlos Chagas in 1909, one of the few instances in medical history where a single scientist discovered both the causative agent and the vector of a new disease. The organism belongs to the order Trypanosomatida, a group of flagellated protozoa that includes the causative agents of African sleeping sickness (T. brucei) and leishmaniasis (Leishmania spp.).
The Kinetoplast: The defining feature of Kinetoplastea is the kinetoplast. A uniquely large, condensed mitochondrial DNA network containing thousands of interlocked circular DNA molecules (maxicircles and minicircles). It is located at the base of the flagellum and is visible under light microscopy. It has no equivalent in any other eukaryote.
Relationship to Other Trypanosomatids
Trypanosoma brucei
Causes African sleeping sickness (HAT). Extracellular in blood. Transmitted by tsetse flies. Does not have an intracellular amastigote stage, the key biological distinction from T. cruzi.
Leishmania spp.
Causes leishmaniasis. Intracellular in macrophages. Transmitted by sandflies. Shares the kinetoplast and flagellum with trypanosomes but belongs to a separate genus. Drug targets partially overlap.
Trypanosoma rangeli
Infects humans but is non-pathogenic. Shares vectors with T. cruzi, particularly Rhodnius prolixus. Serological cross-reactivity complicates Chagas diagnostics in co-endemic areas.
Discrete Typing Units (DTUs)
Trypanosoma cruzi is not a single uniform organism. It comprises a complex of genetically distinct lineages, Discrete Typing Units (DTUs), designated TcI through TcVI, plus the recently described Tcbat. Each DTU has distinct geographic distribution, host associations, vector associations, and clinical correlates. This genetic diversity is one reason drug development is so difficult: a compound effective against one DTU may be less active against another.
| DTU | Geographic Range | Primary Host Associations | Primary Vectors | Clinical Notes |
|---|---|---|---|---|
| TcI | Throughout Latin America; dominant in N. South America, C. America | Opossums (Didelphis spp.), humans | Rhodnius prolixus, Triatoma dimidiata | Dominant DTU in human Chagas disease north of Amazon. Associated with cardiac disease. |
| TcII | Southern South America | Humans, armadillos, primates | Triatoma infestans | Southern Cone. Strong association with cardiac and digestive chronic Chagas. |
| TcIII | Amazon basin, Brazil | Armadillos (Dasypus spp.) | Various sylvatic species | Primarily sylvatic. Rare in human disease. |
| TcIV | Amazon basin, North America | Raccoons, opossums, woodrats | Various Triatoma spp. | Sylvatic cycle in North America. Documented in human cases in USA. |
| TcV | Southern Cone (Paraguay, Bolivia, Argentina) | Humans, domestic animals | Triatoma infestans | Hybrid lineage (TcII × TcIII). Dominant in Southern Cone human disease. Associated with megasyndromes. |
| TcVI | Southern Cone | Humans, domestic animals | Triatoma infestans | Hybrid lineage (TcII × TcIII). Co-circulates with TcV. Clinical profile similar. |
| Tcbat | Brazil, Colombia, Panama | Bats (Carollia spp.) | Bat-associated triatomines | Described 2013. Distinct lineage. Zoonotic potential under investigation. |
Hybrid DTUs and Drug Resistance: TcV and TcVI are hybrid lineages generated by ancient genetic exchange between TcII and TcIII. Their mosaic genomes complicate both taxonomy and drug susceptibility prediction. Benznidazole and nifurtimox efficacy varies across DTUs, a major obstacle to standardized treatment protocols.
Genome and Genetic Data
The T. cruzi genome is unusually complex, large, repetitive, and highly variable between strains. The reference genome (CL Brener, a TcVI hybrid strain) was sequenced in 2005 and revealed remarkable features including massive expansion of multigene families involved in host cell invasion and immune evasion.
Chromosomes: ~41 pairs of homologous chromosomes (estimated; no cytological karyotype)
Protein-coding genes: ~12,000 (CL Brener reference) · ~50% in large multigene families
GC content: ~51%
Reference strain: CL Brener (TcVI hybrid) · NCBI: GCA_000209065.1
Database: TriTrypDB (tritrypdb.org) · part of VEuPathDB consortium
Key multigene families: trans-sialidases (~1,400 genes), mucins (~900), MASP (~1,300), gp63
Key Gene Families and Drug Targets
Trans-Sialidases (TS)
~1,400 genes, the largest gene family in the genome. TS enzymes transfer sialic acid from host glycoproteins to parasite mucins, enabling immune evasion and host cell invasion. Major vaccine candidate antigens.
Mucin / MUCII Superfamily
Coat the parasite surface. Highly variable between strains, key to antigenic diversity and evasion of antibody responses. The extreme variability makes antibody-based vaccines difficult.
Cruzipain (Cruzain)
Major cysteine protease. Essential for parasite survival in host cells. Validated drug target, cruzain inhibitors (e.g., K777) have shown preclinical efficacy. One of the strongest drug target candidates in the pipeline.
CYP51 (Sterol 14α-demethylase)
Ergosterol biosynthesis enzyme. Target of azole antifungals (posaconazole, ravuconazole). Clinical trials of azoles in Chagas disease failed to show parasitological cure despite initial promise, CYP51 inhibition alone is insufficient.
Kinetoplast DNA (kDNA)
~20% of total cellular DNA. Composed of ~50 maxicircles (encoding mitochondrial proteins) and ~10,000 minicircles (encoding guide RNAs for RNA editing). Target of some experimental compounds.
NTR (Nitroreductase)
Type I nitroreductase activates benznidazole and nifurtimox by reducing their nitro groups to reactive intermediates. Loss-of-function mutations in NTR confer drug resistance in laboratory strains, a resistance mechanism to monitor in field isolates.
| Species | Genome (Mb) | Protein-coding genes | %GC | Reference strain |
|---|---|---|---|---|
| T. cruzi | ~110–120 | ~12,000 | 51 | CL Brener · GCA_000209065.1 |
| T. brucei | ~26 | ~9,000 | 46 | TREU927 · GCA_000002125.2 |
| Leishmania major | ~33 | ~8,300 | 59 | Friedlin · GCA_000002725.1 |
Life Cycle of Trypanosoma cruzi
T. cruzi has one of the most complex life cycles of any human pathogen, cycling through morphologically and biochemically distinct stages in both the insect vector and the mammalian host. Each stage has distinct surface antigens, metabolic requirements, and drug susceptibilities.
Morphological Stages
Epimastigote
Location: Midgut of triatomine vector.
Replicating form in the insect. Kinetoplast anterior to nucleus. Not infective to mammals. Differentiates to metacyclic trypomastigote in hindgut.
Metacyclic Trypomastigote
Location: Hindgut / feces of triatomine.
Infective stage deposited in feces during blood meal. Non-replicating. Invades mammalian cells at bite site or mucous membranes. Kinetoplast posterior to nucleus.
Amastigote
Location: Cytoplasm of mammalian host cells.
Intracellular replicating form. Ovoid, ~2–4 µm. Flagellum rudimentary. Multiplies by binary fission. Fills and lyses host cell → releases trypomastigotes. Primary target of drug action.
Bloodstream Trypomastigote
Location: Blood of mammalian host.
Non-replicating. Infects new cells or ingested by feeding triatomine. C-shaped or S-shaped morphology. Kinetoplast subterminal, posterior. The diagnostic form in acute phase blood smears.
Transmission Cycle
| Route | Frequency | Notes |
|---|---|---|
| Vector-borne (triatomine feces) | Primary (historically) | Feces deposited on skin during blood meal; rubbed into bite wound or mucous membranes. Not direct bite transmission. |
| Oral (contaminated food/drink) | Increasingly significant | Outbreaks linked to açaí, sugarcane juice, guava. Particularly severe acute disease. Multiple outbreaks in Brazil and Venezuela. |
| Congenital (mother to infant) | ~1–10% of infected mothers | Major source of new infections outside endemic areas. Treatable if diagnosed early. Global spread mechanism. |
| Blood transfusion | Controlled in most endemic countries | Blood screening mandatory in Latin America since ~1990s. Risk in non-endemic countries with immigrant donors. |
| Organ transplantation | Rare | Documented reactivation in immunosuppressed recipients from infected donors. |
| Laboratory accident | Very rare | Occupational exposure in research settings. |
Oral Transmission Surge: Foodborne Chagas disease outbreaks via contaminated beverages have become increasingly important in several Amazonian settings, particularly Brazil and Venezuela. Oral transmission causes more severe acute disease than vector transmission, with higher rates of myocarditis and mortality in outbreak settings.
Triatominae: The Kissing Bugs
The Triatominae (Family Reduviidae, subfamily Triatominae) are blood-sucking hemipterans, the assassin bug lineage. Over 140 species are known; approximately 30 are epidemiologically significant as vectors of T. cruzi. They are distributed across the Americas from the southern United States to Patagonia, with a few species in Asia and Africa. All are obligate hematophages in all life stages.
Transmission mechanism: Triatomines do not transmit T. cruzi through their bite. Infective metacyclic trypomastigotes are shed in feces during or after the blood meal. Infection occurs when feces are rubbed into the bite wound, eyes, or other mucous membranes, often by the host scratching the bite site.
Epidemiologically Important Species
Region: Southern Cone (Bolivia, Argentina, Brazil, Chile, Paraguay, Uruguay)
Status: Primary domestic vector. Target of the Southern Cone Initiative, largely eliminated from Argentina, Chile, Uruguay, Brazil (pending); Bolivia remains a reservoir.
- Highly domesticated; lives in wall cracks, roof thatch
- Most important historical vector for TcV/TcVI DTUs
- Insecticide resistance (pyrethroid) documented in Bolivia
Region: Venezuela, Colombia, Central America
Status: Eliminated from Central America except Guatemala (ongoing). Persists in Venezuela and Colombia.
- Classic laboratory model, used by Chagas himself
- Highly domestic; palm-thatch roofs
- Vector for TcI DTU
- R. prolixus genome sequenced 2015
Region: Mexico, Central America, Colombia, Ecuador, Peru
Status: Partially domestic; re-invades from sylvatic habitats. Control more difficult than T. infestans.
- Sylvatic + domestic cycle
- Seasonal migration into houses
- Vector for TcI; important in Yucatán, Guatemala
Region: Brazil (Atlantic forest zone)
Status: Secondary domestic vector in Brazil; sylvatic reservoir species.
- Large species; highly mobile
- Associated with TcII/TcVI
- Important where T. infestans has been controlled
Region: Southern United States (Texas, New Mexico, Arizona)
Status: Sylvatic; occasionally enters homes. Associated with autochthonous US Chagas cases.
- ~300,000 estimated infected in USA, mostly via congenital/transfusion
- Vector transmission documented in Texas
- TcIV DTU dominant in US sylvatic cycle
Region: Baja California, Mexico
Status: Large domestic/peridomestic species. One of the largest triatomines (~45 mm).
- Important local vector in Baja Peninsula
- Takes very large blood meals, efficient vector
- Used in laboratory xenodiagnosis
Clinical Disease, Three Phases
Chagas disease progresses through three clinical phases with markedly different presentations, treatability, and outcomes. The transition from acute to chronic is the defining feature of the disease, and the reason so many cases are never diagnosed.
Acute Phase
Duration: 4–8 weeks after infection
Parasitaemia: High, detectable in blood smear
Usually mild or asymptomatic. Classic signs: Romaña's sign (painless periorbital oedema from conjunctival entry), chagoma (indurated skin lesion at bite site), fever, malaise, lymphadenopathy, hepatosplenomegaly.
Severe acute disease (rare, ~1–5%): myocarditis, meningoencephalitis, high mortality, especially in young children and immunocompromised.
Treatment: Benznidazole or nifurtimox achieves parasitological cure in ~80% if treated during acute phase.
Indeterminate (Chronic Asymptomatic) Phase
Duration: Years to decades, lifelong in ~70% of chronically infected
Parasitaemia: Very low; intermittent
No symptoms. Normal ECG, normal echocardiogram, normal chest X-ray. Serology positive. Parasite detectable only by PCR or xenodiagnosis. Patients are entirely unaware.
The diagnostic gap lives here. Global estimates of 6–7 million infected are likely severe undercounts.
Treatment efficacy controversial in adults, see treatment section.
Chronic Symptomatic Phase
Develops in: ~30% of infected individuals, typically after 10–30 years
Parasitaemia: Very low; damage is immune-mediated
Cardiac form (Chagasic cardiomyopathy): The most dangerous manifestation. Dilated cardiomyopathy, arrhythmias (including life-threatening ventricular tachycardia), apical aneurysm, heart block, sudden cardiac death. Leading cause of cardiac death in Latin America aged 30–50.
Digestive form: Megaoesophagus (dysphagia, regurgitation) and megacolon (constipation, obstruction), caused by destruction of myenteric ganglia. Predominantly Southern Cone, associated with TcV/TcVI.
Mixed form: Cardiac + digestive manifestations.
Treatment: Antiparasitic drugs do not reverse established cardiac or digestive damage. Management is symptomatic, antiarrhythmics, ICD implantation, cardiac transplantation.
Reactivation in Immunosuppression: In HIV/AIDS co-infection or post-transplant immunosuppression, chronic T. cruzi infection can reactivate dramatically, producing meningoencephalitis and severe myocarditis with high mortality. Brain lesions may mimic cerebral toxoplasmosis. Chagas serology should be mandatory before immunosuppressive therapy in endemic or at-risk populations.
Current Treatments and Contraindications
Only two drugs are approved for the treatment of Chagas disease, benznidazole and nifurtimox, both developed in the 1960s and 1970s. Neither was designed for T. cruzi specifically. Both have significant toxicity profiles and limited efficacy in the chronic phase. This is the starkest example of the neglected disease funding gap in all of tropical medicine.
No approved treatment for chronic adult Chagas disease in most countries outside Argentina and Brazil. The BENEFIT trial (2015, NEJM) showed that benznidazole in adults with established Chagas cardiomyopathy reduced parasitaemia but did not reduce cardiac events or mortality. This remains the central unresolved clinical question.
Approved Antiparasitic Drugs
Benznidazole
First-lineMechanism: Prodrug activated by T. cruzi type I nitroreductase (NTR) → reactive nitro radical intermediates → DNA damage, protein adducts, lipid peroxidation.
Dose: 5–7 mg/kg/day in two divided doses for 60 days (adults); up to 10 mg/kg/day in children.
Efficacy: ~80% cure in acute phase; ~60% in congenital; ~20–40% in chronic indeterminate phase (variable by DTU and region).
Adverse effects: Dermatitis (most common, up to 30%), peripheral neuropathy (dose-limiting), anorexia, nausea, leukopenia. Requires full 60-day course, tolerability is a major compliance barrier.
Nifurtimox
First-line (alternative)Mechanism: Prodrug → nitroanion radical → oxidative stress; also inhibits trypanothione reductase (parasite-specific glutathione analog).
Dose: 8–10 mg/kg/day in 3–4 doses for 60–90 days (adults); 15–20 mg/kg/day in children.
Efficacy: Comparable to benznidazole. May be more active against some DTUs. Used when benznidazole is unavailable or not tolerated.
Adverse effects: Anorexia, weight loss, neuropsychiatric effects (insomnia, irritability, tremor), peripheral neuropathy, GI disturbance. Generally considered less well tolerated than benznidazole in adults.
Contraindications and Cautions
Pregnancy
ContraindicatedBoth benznidazole and nifurtimox are contraindicated in pregnancy. Teratogenic in animal studies. Treatment is generally deferred during pregnancy, and withholding treatment during breastfeeding is recommended unless specialist guidance indicates otherwise. Congenital transmission risk (~5%) must be managed by neonatal screening and early treatment of the infant.
Severe Hepatic or Renal Impairment
ContraindicatedBoth drugs are hepatically metabolised. Significant renal or hepatic impairment contraindicates use. Liver function tests and CBC monitoring required during treatment.
Chronic Phase, Adult Cardiac Disease
Caution, Evidence LimitedThe BENEFIT trial (2015) showed benznidazole reduced parasitaemia in chronic cardiomyopathy but did not reduce cardiac events or mortality at 5 years. Treatment of asymptomatic adults in indeterminate phase remains clinician judgment, guidelines differ between countries.
Azole Antifungals (Posaconazole, Ravuconazole)
Failed Phase II/IIICYP51 inhibitors showed early promise. CHAGASAZOL trial (posaconazole) and STOP-CHAGAS trial showed suppression of parasitaemia but no sustained cure and high relapse rates. Not recommended outside clinical trials.
WHO Treatment Indications by Phase and Age
| Patient Group | Treatment Recommended? | Expected Efficacy | Drug / Duration |
|---|---|---|---|
| Acute phase (any age) | Yes, strongly | ~80% parasitological cure | Benznidazole 60 days (preferred) |
| Congenital infection (infant) | Yes, strongly | ~95% if treated <1 year of age | Benznidazole 60 days |
| Children <12 years, chronic | Yes | ~60–70% | Benznidazole 60 days |
| Adolescents / adults, indeterminate chronic | Recommended (WHO) | ~20–40%; uncertain cardiac benefit | Benznidazole 60 days; shared decision-making |
| Adults with established cardiomyopathy | Uncertain, BENEFIT trial negative | Parasitological benefit; no cardiac benefit shown | Individualized; clinical trial preferred |
| Reactivation (HIV, transplant) | Yes, urgently | Variable; high mortality if untreated | Benznidazole; consider nifurtimox if resistant |
| Pregnancy | No, contraindicated | N/A | Defer; treat infant if congenital transmission confirmed |
Drug Pipeline and Future Directions
The Chagas disease drug pipeline is thin but growing, driven primarily by the Drugs for Neglected Diseases initiative (DNDi) and academic partnerships. After decades of near-zero pharmaceutical industry investment, the 2010s saw renewed interest, partly catalysed by the azole trial failures, which paradoxically clarified the need for better targets.
Benznidazole Pediatric Formulation Approved 2017
Age-appropriate dispersible tablet for children under 2 years (Lafepe/DNDi partnership). A landmark access achievement, the first new formulation in decades. Addresses the highest-efficacy treatment window.
Fexinidazole Phase II
Fexinidazole was evaluated for chronic indeterminate Chagas disease but is no longer being developed as monotherapy after Phase II results showed tolerability without sustained parasite clearance.
Acoziborole (SCYX-7158) Phase II/III, HAT
Benzoxaborole class. CNS-penetrant. Developed for HAT (sleeping sickness) but evaluated for potential Chagas activity. Single-dose oral formulation, a transformative delivery advantage if applicable.
Cruzain (Cysteine Protease) Inhibitors Preclinical
K777 and related vinyl sulfone inhibitors target cruzipain, the major cysteine protease essential for amastigote survival. Strong preclinical data; K777 advanced to IND filing. Pandemic disrupted development timeline. DNDi and UCSF leading.
Trypanothione Reductase Inhibitors Preclinical
Trypanothione replaces glutathione in all trypanosomatids, absent in humans, making it an ideal selective target. Multiple chemical series in optimization. No human toxicity liability by design.
mRNA / Therapeutic Vaccines Research
Trans-sialidase antigens (Tc24, TSA-1) in adjuvanted formulations showing promise in mouse models. No clinical candidate yet. A prophylactic vaccine for Chagas faces the complexity of 7 DTUs with divergent surface antigens.
AI-Assisted Drug Discovery Active
DNDi and Open Source Pharma partnerships using ML compound screening against T. cruzi amastigote phenotypic assays. The TriTrypDB genomic database enables target identification across all trypanosomatids simultaneously.
The DNDi Model: The Drugs for Neglected Diseases initiative (DNDi, Geneva) is the dominant force in Chagas drug development, a non-profit product development partnership funded by MSF, governments, and foundations. It operates where pharmaceutical markets have failed entirely. Without DNDi, there would be essentially no active Chagas pipeline.
Postulated Path to Control and Elimination
Eradication of Chagas disease is not currently on the scientific agenda in the way malaria eradication is, the biology is different, the chronic burden is already enormous, and the tools are far less mature. The realistic goal is elimination of transmission and universal access to diagnosis and treatment for those already infected. That goal is achievable within a generation with sufficient political will.
Integrated Chagas Control Framework
Vector Control at Scale
Indoor residual spraying with pyrethroids remains the most effective intervention. The Southern Cone Initiative eliminated T. infestans from Uruguay, Chile, and most of Brazil and Argentina. Bolivia, the highest-burden country, requires renewed commitment and resistance management.
Universal Neonatal and Congenital Screening
Every infant born to a seropositive mother must be tested and treated. Congenital Chagas is the primary transmission route outside Latin America, and the most treatable form, with ~95% cure if treated under 1 year of age.
Blood and Organ Donation Screening
Mandatory serological screening of all blood donations in endemic and high-immigration countries. Donor screening in the USA, Spain, and other non-endemic countries with large Latin American populations requires consistent enforcement.
New Drugs for Chronic Phase Adults
The BENEFIT trial defined the problem; it did not solve it. A drug that achieves parasitological cure and prevents cardiac progression in adult chronic Chagas would transform the disease. Fexinidazole and cruzain inhibitors are the current best candidates.
Point-of-Care Diagnostics
Chagas requires two positive serological tests using different antigens for confirmation, a barrier to diagnosis in rural settings. Rapid diagnostic tests (RDTs) with high sensitivity/specificity are needed for primary care deployment throughout endemic areas.
Housing Improvement
Triatomine domestication depends on mud walls, thatched roofs, and cracks in adobe construction. Plastered walls and improved housing, a social determinant intervention, is the most durable vector control. This is a development problem as much as a public health problem.
Scientific Assessment: Elimination of T. cruzi transmission is achievable with existing vector control tools, expanded screening, and improved housing. The 6–7 million people currently infected represent a chronic burden that will persist for decades regardless of transmission control, requiring sustained access to diagnosis, treatment (improved drugs urgently needed), and cardiac care. The gap is not science. It is money, political will, and the persistent classification of a disease that kills 12,000 people per year as "neglected."
Sources and References
All information drawn from government agencies, international health organizations, and peer-reviewed scientific literature.
Government and Intergovernmental Organizations
- World Health Organization (WHO). Chagas Disease (American Trypanosomiasis), Fact Sheet. who.int
- PAHO/WHO. Chagas Disease, Regional Initiative. paho.org
- U.S. CDC. Chagas Disease, Parasites. cdc.gov
- NCBI / NIH. Trypanosoma cruzi CL Brener genome assembly. GCA_000209065.1. ncbi.nlm.nih.gov
NGOs and Research Institutions
- DNDi (Drugs for Neglected Diseases initiative). Chagas Disease Portfolio. dndi.org
- TriTrypDB / VEuPathDB. Trypanosomatid genomics database. tritrypdb.org
- Mundo Sano Foundation. Chagas global burden data.
Peer-Reviewed Literature
- El-Sayed NM, Myler PJ, Bartholomeu DC, et al. 2005. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309(5733):409–415. doi: 10.1126/science.1112631. Science
- Jansen AM, Xavier SCDC, Roque ALR. 2018. Trypanosoma cruzi transmission in the wild and its most important reservoir hosts in Brazil. Parasites & Vectors 11:502. doi: 10.1186/s13071-018-3067-2. PMID: 30189896; PMCID: PMC6127949. PubMed
- Flores-Ferrer A, Waleckx E, Rascalou G, Dumonteil E, Gourbière S. 2019. Trypanosoma cruzi transmission dynamics in a synanthropic and domesticated host community. PLOS Neglected Tropical Diseases 13(12):e0007902. doi: 10.1371/journal.pntd.0007902. PLOS Neglected Tropical Diseases
- Noireau F, Diosque P, Jansen AM. 2009. Trypanosoma cruzi: adaptation to its vectors and its hosts. Veterinary Research 40:26. doi: 10.1051/vetres/2009009. PubMed Central
- Morillo CA, Marin-Neto JA, Avezum A, et al. 2015. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine 373:1295–1306. doi: 10.1056/NEJMoa1507574. NEJM
- Zingales B, Miles MA, Campbell DA, et al. 2012. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infection, Genetics and Evolution 12(2):240–253. doi: 10.1016/j.meegid.2011.12.009. PubMed
- Bern C. 2015. Chagas' disease. New England Journal of Medicine 373:456–466. doi: 10.1056/NEJMra1410150. NEJM
- Velásquez-Ortiz N, Herrera G, Hernández C, Muñoz M, Ramírez JD. 2022. Discrete typing units of Trypanosoma cruzi: geographical and biological distribution in the Americas. Scientific Data 9:360. doi: 10.1038/s41597-022-01452-w. PMID: 35750679; PMCID: PMC9232490. PubMed Central